Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased risk

Affiliations

Robert K. Lesniak: Medicinal Chemistry Knowledge Center, Sarafan Chemistry, Engineering and Medicine for Human Health, Stanford University, Stanford, CA, United States
Robert K. Lesniak: Department of Pathology, Stanford University, Stanford, CA, United States
R. Jeremy Nichols: Department of Pathology, Stanford University, Stanford, CA, United States
Thomas J. Montine: Department of Pathology, Stanford University, Stanford, CA, United States

Abstract

No abstracts available.

ISSN: 1664-2295 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry: Neurology. Diseases of the nervous system
Website: https://www.frontiersin.org/journals/neurology/